Vistagen gets Nasdaq extension on $1 bid rule
Vistagen Therapeutics, Inc. reports that Nasdaq has granted a 180-day extension, until February 1, 2027, to regain compliance with the $1.00 per share Minimum Bid Price Requirement for its common stock to remain listed on the Nasdaq Capital Market.
Rhea-AI Filing Summary
Vistagen Therapeutics, Inc. reports that Nasdaq has granted a 180-day extension, until February 1, 2027, to regain compliance with the $1.00 per share Minimum Bid Price Requirement for its common stock to remain listed on the Nasdaq Capital Market.
The extension does not immediately affect the stock’s listing, which remains fully effective. Vistagen has informed Nasdaq it intends to cure the deficiency within the extension period. If compliance is not restored by that deadline, the common stock would be subject to delisting, and any appeal to a Nasdaq Hearing Panel is not assured of success.
Positive
- None.
Negative
- Nasdaq delisting risk if compliance not regained: Vistagen’s common stock remains below the $1.00 Minimum Bid Price Requirement and must regain compliance by February 1, 2027 or it will be subject to delisting, with any appeal to a Nasdaq Hearing Panel offering no assurance of success.
8-K Event Classification
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
1 item
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Key Figures
Extension Period: 180 days
Extension Deadline: February 1, 2027
Minimum Bid Price Requirement: $1.00 per share
+1 more
4 metrics
Extension Period
180 days
Length of Nasdaq bid-price compliance extension granted on August 4, 2026
Extension Deadline
February 1, 2027
Date by which Vistagen must regain compliance with the Nasdaq Minimum Bid Price Requirement
Minimum Bid Price Requirement
$1.00 per share
Required minimum bid price for Vistagen common stock under Nasdaq Listing Rule 5550(a)(2)
Noncompliance Period
30 consecutive business days
Duration Vistagen’s stock stayed below $1.00 before the initial Nasdaq notice disclosed February 6, 2026
Key Terms
Minimum Bid Price Requirement, Nasdaq Capital Market, Nasdaq Listing Rule 5550(a)(2), Nasdaq Hearing Panel
4 terms
Minimum Bid Price Requirement regulatory
"to maintain a minimum bid price of $1.00 per share for continued listing"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Capital Market regulatory
"for continued listing on the Nasdaq Capital Market"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
Nasdaq Listing Rule 5550(a)(2) regulatory
"as set forth in Nasdaq Listing Rule 5550(a)(2)"
Nasdaq Hearing Panel regulatory
"the Company may appeal Nasdaq’s delisting determination to a Nasdaq Hearing Panel"
A Nasdaq hearing panel is a group of independent reviewers who decide whether a publicly listed company has broken the exchange’s rules and what penalties, if any, should apply. Think of it like a neighborhood committee that reviews complaints and can impose fines, require fixes, or remove a member; for investors, the panel’s rulings can affect whether a stock keeps trading, faces suspension, or suffers reputational and price impact.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Nasdaq extension did Vistagen Therapeutics (VTGN) receive?
Vistagen received a 180-day extension from Nasdaq, giving the company until February 1, 2027 to regain compliance with the $1.00 per share Minimum Bid Price Requirement for its common stock to continue trading on the Nasdaq Capital Market.
Does the Nasdaq extension change Vistagen (VTGN)’s current listing status?
The extension has no immediate effect on Vistagen’s listing status. Its common stock continues to trade on the Nasdaq Capital Market, and the company’s listing remains fully effective while it works to regain compliance within the extension period.
What happens if Vistagen (VTGN) does not regain Nasdaq bid-price compliance?
If Vistagen does not restore the $1.00 bid price by February 1, 2027, Nasdaq will issue written notice that the common stock is subject to delisting. The company could appeal to a Nasdaq Hearing Panel, but there is no assurance any appeal would succeed.
How did Vistagen (VTGN) first fall out of Nasdaq bid-price compliance?
Nasdaq previously notified Vistagen, as disclosed in a filing on February 6, 2026, that its common stock had failed to meet the $1.00 Minimum Bid Price Requirement for 30 consecutive business days, triggering the initial compliance deficiency process.
AI-generated analysis. How Rhea-AI works. Not financial advice.
